<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326856</url>
  </required_header>
  <id_info>
    <org_study_id>ET-01-LCL-206</org_study_id>
    <nct_id>NCT03326856</nct_id>
  </id_info>
  <brief_title>ET-01 in Subjects With Lateral Canthal Lines</brief_title>
  <official_title>Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eirion Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eirion Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A,&#xD;
      topical, in lateral canthal lines (LCL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This product is being tested for its ability to reduce lateral canthal lines, also known as&#xD;
      Crow's Feet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Actual">November 14, 2018</completion_date>
  <primary_completion_date type="Actual">June 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>sequential, dose escalating study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2</measure>
    <time_frame>Week 4</time_frame>
    <description>Composite of Investigators Global Assessment &amp; Subject Self-Assessment on contraction.&#xD;
Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be &quot;responders&quot; defined as Score ≤ 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of Observations With a Response Defined as IGA-C Score ≤ 2</measure>
    <time_frame>Week 2, 4, 8,12,18</time_frame>
    <description>Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a &quot;responder&quot; is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Observations With a Response Defined as SSA-C Score ≤ 2</measure>
    <time_frame>Week 2, 4, 8,12,18</time_frame>
    <description>Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a &quot;responder&quot; is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <condition>Crow's Feet</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin, Type A, Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin, Type A, Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin, Type A, Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin, Type A, Dose 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin, Type A</intervention_name>
    <description>topical liniment</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <other_name>ET-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Formulation</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  25 - 65 years of age&#xD;
&#xD;
          -  minimal to moderate Crow's Feet wrinkles at rest&#xD;
&#xD;
          -  moderate to severe Crow's Feet wrinkles on contraction&#xD;
&#xD;
          -  willingness to refrain from any product affecting skin remodeling&#xD;
&#xD;
          -  female subjects must be not pregnant and non-lactating-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of adverse reactions to any prior botulinum toxin treatments&#xD;
&#xD;
          -  history of vaccination or non-response to any prior botulinum toxin treatments&#xD;
&#xD;
          -  botulinum toxin treatment in the prior 6 months&#xD;
&#xD;
          -  present or history of neuromuscular disease, eyelid ptosis, muscle weakness,&#xD;
             paralysis, or &quot;dry eye&quot;&#xD;
&#xD;
          -  history of peri-ocular surgery, brow lift or related procedures&#xD;
&#xD;
          -  procedures affecting the lateral canthal region in the prior 12 months&#xD;
&#xD;
          -  application of topical prescription medication to the treatment area&#xD;
&#xD;
          -  female subjects who are pregnant or are nursing a child&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Theobald, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eirion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cary Skin Care</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <results_first_submitted>June 29, 2021</results_first_submitted>
  <results_first_submitted_qc>August 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2021</results_first_posted>
  <disposition_first_submitted>July 1, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 15, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 10, 2021</disposition_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03326856/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vehicle</title>
          <description>Vehicle&#xD;
Vehicle: Vehicle Formulation</description>
        </group>
        <group group_id="P2">
          <title>Dose 1</title>
          <description>botulinum toxin, Type A, topical liniment Dose 1x on Day 0</description>
        </group>
        <group group_id="P3">
          <title>Dose 2</title>
          <description>botulinum toxin, Type A, topical liniment Dose 1.8x on Day 0</description>
        </group>
        <group group_id="P4">
          <title>Dose 3</title>
          <description>botulinum toxin, Type A, topical liniment Dose 2.5x on Day 0</description>
        </group>
        <group group_id="P5">
          <title>Dose 4</title>
          <description>botulinum toxin, Type A, topical liniment Dose 3.5x on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle</title>
          <description>Vehicle&#xD;
Vehicle: Vehicle Formulation</description>
        </group>
        <group group_id="B2">
          <title>Dose 1</title>
          <description>botulinum toxin, Type A, topical liniment Dose 1x on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Dose 2</title>
          <description>botulinum toxin, Type A, topical liniment Dose 1.8x on Day 0</description>
        </group>
        <group group_id="B4">
          <title>Dose 3</title>
          <description>botulinum toxin, Type A, topical liniment Dose 2.5x on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Dose 4</title>
          <description>botulinum toxin, Type A, topical liniment Dose 3.5x on Day 0</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IGA-C</title>
          <description>Investigator Global Assessment on Contraction using the ordinal Crow's Feet Wrinkle Scale where severity is scored between 0=absent and 4=severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="0.4"/>
                    <measurement group_id="B2" value="3.6" spread="0.5"/>
                    <measurement group_id="B3" value="3.4" spread="0.5"/>
                    <measurement group_id="B4" value="3.4" spread="0.5"/>
                    <measurement group_id="B5" value="3.5" spread="0.5"/>
                    <measurement group_id="B6" value="3.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SSA-C</title>
          <description>Subject Self-Assessment on Contraction using the ordinal Crow's Feet Wrinkle Scale where severity is scored between 0=absent and 4=severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="0.5"/>
                    <measurement group_id="B2" value="3.6" spread="0.5"/>
                    <measurement group_id="B3" value="3.4" spread="0.5"/>
                    <measurement group_id="B4" value="3.5" spread="0.5"/>
                    <measurement group_id="B5" value="3.4" spread="0.5"/>
                    <measurement group_id="B6" value="3.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2</title>
        <description>Composite of Investigators Global Assessment &amp; Subject Self-Assessment on contraction.&#xD;
Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be &quot;responders&quot; defined as Score ≤ 2.</description>
        <time_frame>Week 4</time_frame>
        <population>Per Protocol (PP) population defined as all treated subjects who had at least one post-baseline visit. No imputation was performed when only incomplete data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Vehicle&#xD;
Vehicle: Vehicle Formulation</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>botulinum toxin, Type A, topical liniment Dose 1x on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>botulinum toxin, Type A, topical liniment Dose 1.8x on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>botulinum toxin, Type A, topical liniment Dose 2.5x on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dose 4</title>
            <description>botulinum toxin, Type A, topical liniment Dose 3.5x on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2</title>
          <description>Composite of Investigators Global Assessment &amp; Subject Self-Assessment on contraction.&#xD;
Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be &quot;responders&quot; defined as Score ≤ 2.</description>
          <population>Per Protocol (PP) population defined as all treated subjects who had at least one post-baseline visit. No imputation was performed when only incomplete data were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Observations With a Response Defined as IGA-C Score ≤ 2</title>
        <description>Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a &quot;responder&quot; is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.</description>
        <time_frame>Week 2, 4, 8,12,18</time_frame>
        <population>Per Protocol (PP) population defined as all treated subjects who had at least one post-baseline visit. No imputation was performed when only incomplete data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Vehicle&#xD;
Vehicle: Vehicle Formulation</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>botulinum toxin, Type A, topical liniment Dose 1x on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>botulinum toxin, Type A, topical liniment Dose 1.8x on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>botulinum toxin, Type A, topical liniment Dose 2.5x on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dose 4</title>
            <description>botulinum toxin, Type A, topical liniment Dose 3.5x on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Observations With a Response Defined as IGA-C Score ≤ 2</title>
          <description>Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a &quot;responder&quot; is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.</description>
          <population>Per Protocol (PP) population defined as all treated subjects who had at least one post-baseline visit. No imputation was performed when only incomplete data were available.</population>
          <units>Observations</units>
          <param>Count of Units</param>
          <units_analyzed>Observations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Observations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Observations With a Response Defined as SSA-C Score ≤ 2</title>
        <description>Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a &quot;responder&quot; is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.</description>
        <time_frame>Week 2, 4, 8,12,18</time_frame>
        <population>Per Protocol (PP) population defined as all treated subjects who had at least one post-baseline visit. No imputation was performed when only incomplete data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Vehicle&#xD;
Vehicle: Vehicle Formulation</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>botulinum toxin, Type A, topical liniment Dose 1x on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>botulinum toxin, Type A, topical liniment Dose 1.8x on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>botulinum toxin, Type A, topical liniment Dose 2.5x on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dose 4</title>
            <description>botulinum toxin, Type A, topical liniment Dose 3.5x on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Observations With a Response Defined as SSA-C Score ≤ 2</title>
          <description>Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a &quot;responder&quot; is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.</description>
          <population>Per Protocol (PP) population defined as all treated subjects who had at least one post-baseline visit. No imputation was performed when only incomplete data were available.</population>
          <units>Observations</units>
          <param>Count of Units</param>
          <units_analyzed>Observations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Observations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>26 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>Vehicle&#xD;
Vehicle: Vehicle Formulation</description>
        </group>
        <group group_id="E2">
          <title>Dose 1</title>
          <description>botulinum toxin, Type A, topical liniment Dose 1x on Day 0</description>
        </group>
        <group group_id="E3">
          <title>Dose 2</title>
          <description>botulinum toxin, Type A, topical liniment Dose 1.8x on Day 0</description>
        </group>
        <group group_id="E4">
          <title>Dose 3</title>
          <description>botulinum toxin, Type A, topical liniment Dose 2.5x on Day 0</description>
        </group>
        <group group_id="E5">
          <title>Dose 4</title>
          <description>botulinum toxin, Type A, topical liniment Dose 3.5x on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>PRIOR MYOCARDIAL INFARCTION NOTED ON ECG PRIOR TO STUDY DRUG ADMINISTRATION. CONFIRMED AT WEEK 2 ECG.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study Results are considered Confidential Information that may not be published or disclosed without Sponsor's written consent for a period of five (5) years after completion of the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Executive Officer</name_or_title>
      <organization>Eirion Therapeutics</organization>
      <phone>(781) 935-1216</phone>
      <email>info@eirionthera.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

